Chippenham, UK – 23 April, 2007: Vectura Group plc (LSE: VEC) (“Vectura”) today announces the successful outcome of a second Phase IIb clinical study for VR004, its product for the treatment of Erectile Dysfunction (ED). The study demonstrated that VR004 again improved erectile performance, with a rapid onset of action, and was well tolerated. VR004 is Vectura’s proprietary formulation of apomorphine, delivered by oral inhalation to the lungs using Vectura’s AspirairÒ dry powder inhaler (DPI).
